Startups
Aera Therapeutics emerged from stealth mode Thursday with a platform based on the work of Feng Zhang, Ph.D. and ex-Alnylam executive Akin Akinc at the helm.
Curie.Bio launched this week with $520 million to take early startups from ground zero through Series A funding.
Due to safety concerns, Aristea Therapeutics announced Friday that it was discontinuing the development of its Phase II lead program. As a result, the San Diego-based biotech is also dissolving its business.
Backed by Versant and Genentech, Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform.
Covalent biologic company Enlaza launches with $61M in seed financing.
Flagship Pioneering has committed $50 million to Montai Health, a biotech that aims to develop therapies for chronic diseases using molecules already found in nature.
With $47 million in hand, Dantari launched Thursday to advance its Targeted High-capacity Drug Conjugate technology – its take on an antibody-drug conjugate - for solid tumors.
Entact Bio launched with $81 million Tuesday to advance its protein enhancement platform.
SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy platform.
PictorLabs emerged from stealth mode Thursday with $18.8 million to advance its AI-powered virtual staining platform that researchers hope will “reimagine the future” of histopathology.
PRESS RELEASES